L818 Press Release Lap Keu Q2 2026.pdf

    Resep Dokter berhasil membukukan Penjualan Neto sebesar Rp6.337,82 miliar atau bertumbuh sebesar
    14,35% jika dibandingkan dengan periode yang sama tahun 2025.
   Divisi Obat Bebas, berhasil membukukan Penjualan Neto sebesar Rp2.603,17 miliar pada Semester pertama
    tahun 2026 dengan kontribusi sebesar 14,25% dan mengalami peningkatan sebesar 9,35% jika
    dibandingkan dengan periode yang sama tahun 2025.
   Divisi Bahan Baku Untuk Dijual mencatatkan Penjualan Neto sebesar Rp1.475,24 miliar pada Semester
    pertama tahun 2026, meningkat 20,11% dibandingkan dengan periode yang sama tahun 2025, serta
    memberikan kontribusi sebesar 8,07%.
   Divisi Peralatan Kesehatan memberikan kontribusi sebesar 4,90% pada Semester pertama tahun 2026,
    dengan angka Penjualan Neto yang tercatat sebesar Rp894,64 miliar, meningkat 17,75% jika dibandingkan
    dengan periode yang sama tahun 2025.
   Penjualan Neto dari Divisi Jasa Layanan Kesehatan dan Pengangkutan tercatat sebesar Rp60,65 miliar,
    meningkat 48,48% jika dibandingkan dengan periode yang sama tahun 2025. Divisi ini memberikan
    kontribusi sebesar 0,33%.
   Penjualan Neto dari Divisi Obat Hewan dan Ternak tercatat sebesar Rp24,72 miliar, menurun 11,15% jika
    dibandingkan dengan periode yang sama tahun 2025 yang tercatat sebesar Rp27,83 miliar. Divisi Obat
    Hewan dan Ternak memberikan kontribusi sebesar 0,14% terhadap total Penjualan Neto Perseroan.



Tentang Enseval
PT Enseval Putera Megatrading Tbk ("Enseval") merupakan salah satu perusahaan distribusi dan logistik
terbesar di Indonesia yang telah memulai kegiatan usahanya sejak tahun 1973. Perseroan menjadi perusahaan
terbuka pada 1 Agustus 1994 dengan kode saham EPMT di Bursa Efek Indonesia.

Selain mendistribusikan produk-produk Kalbe Group, Enseval juga dipercaya oleh berbagai principal nasional
maupun internasional. Perseroan didukung oleh jaringan distribusi yang luas, terdiri atas 3 Pusat Distribusi di
Jakarta, Cikarang, dan Surabaya, 48 cabang yang tersebar di seluruh Indonesia, serta 24 cabang melalui
entitas anak PT Tri Sapta Jaya.

Hingga saat ini, Perseroan memiliki 8 entitas anak yang bergerak di bidang distribusi dan logistik, bahan baku,
peralatan kesehatan, layanan kesehatan, serta jasa pengangkutan.



Jakarta, 31 Juli 2026
-----------------------------
Untuk informasi lebih lanjut, silahkan menghubungi:
Corporate Secretary
PT Enseval Putera Megatrading Tbk.
Gedung Enseval,
Jalan Pulo Lentut No.10
Kawasan Industri Pulo Gadung, Jakarta-13920.
Telp: (021) 4682-2422 Fax: (021) 460-9039
Email: investor.relations@enseval.com

                                               Press Release
                          NET SALES OF PT ENSEVAL PUTERA MEGATRADING TBK
                             GREW BY 13.79% IN THE FIRST SEMESTER OF 2026
                                Press Release No. L818/EPM/CSEC/VII/2026

Jakarta, July 31, 2026 – PT Enseval Putera Megatrading Tbk (the "Company") recorded Net Sales of IDR
18,271.68 billion in the first half of 2026, based on the Company's and its Subsidiaries' Consolidated Financial
Statements for the period ended June 30, 2026 (unaudited). This represents a 13.79% increase compared to Net
Sales of IDR 16,056.77 billion in the first half of 2025, reflecting the Company's sustained business growth.

In line with higher sales, Cost of Goods Sold increased by 13.77% to IDR 16,431.77 billion. Nevertheless, the
Company continued to maintain profitability growth by posting Gross Profit of IDR 1,839.92 billion, representing
an increase of 14.05% compared to the first half of 2025.

Operating Expenses amounted to IDR 1,254.27 billion, comprising Selling Expenses of IDR 1,105.77 billion and
General and Administrative Expenses of IDR 148.49 billion. Operating Expenses increased by 12.41% year-on-
year, in line with the Company's business expansion and operational strengthening. As a result, the Company
recorded Operating Profit of IDR 585.65 billion.

Profit Before Income Tax Expense amounted to IDR 564.58 billion. Other Income (Expenses) consisted of Finance
Income of IDR 5.40 billion, Finance Costs of IDR 11.14 billion, Final Tax Expense of IDR 1.66 billion, Share of Net
Profit of Associates of IDR 5.47 billion, Other Operating Income of IDR 22.06 billion, and Other Operating
Expenses of IDR 41.20 billion.

Meanwhile, Income Tax Expense amounted to IDR 126.30 billion, remaining relatively stable compared to IDR
114.04 billion recorded in the first half of 2025.

Accordingly, the Company posted Profit for the Period of IDR 438.28 billion, representing an increase of 11.54%
compared to the same period last year. This achievement reflects the Company's ability to sustain business
performance amid operational dynamics and evolving market conditions.

Based on the Company's Consolidated Statement of Financial Position as of June 30, 2026 (Unaudited)
compared with December 31, 2025 (Audited), Total Assets increased by 8.66%, from IDR 13.13 trillion to IDR 14.27
trillion. Total Liabilities rose by 13.29%, from IDR 5.27 trillion as of December 31, 2025, to IDR 5.97 trillion in the
first half of 2026. Consequently, Total Equity increased by 5.56%, from IDR 7.87 trillion to IDR 8.30 trillion during
the same period.

Performance of Each Division
The Company currently operates through seven business divisions, namely Consumer Products, Prescription
Pharmaceuticals, Over-the-Counter (OTC) Pharmaceuticals, Raw Materials for Sale, Medical Devices, Healthcare
Services and Transportation, and Veterinary Pharmaceuticals.

The performance details of each division are as follows:
   Consumer Products Division, the Company's largest contributor to Net Sales, accounted for 37.63% of total
    Net Sales. During the first half of 2026, the division recorded Net Sales of IDR 6,875.43 billion, an increase of
    13.14% compared to the same period in 2025.
   Prescription Pharmaceuticals Division, the second-largest contributor, accounted for 34.69% of total Net
    Sales. The division generated Net Sales of IDR 6,337.82 billion in the first half of 2026, representing a 14.35%
    year-on-year increase.
   Over-the-Counter (OTC) Pharmaceuticals Division recorded Net Sales of IDR 2,603.17 billion, contributing
    14.25% of total Net Sales and growing by 9.35% compared to the same period in 2025.

   Raw Materials for Sale Division posted Net Sales of IDR 1,475.24 billion, an increase of 20.11% year-on-year,
    contributing 8.07% of total Net Sales.
   Medical Devices Division contributed 4.90% of total Net Sales, recording Net Sales of IDR 894.64 billion, up
    17.75% compared to the first half of 2025.
   Healthcare Services and Transportation Division recorded Net Sales of IDR 60.65 billion, representing a
    48.48% increase year-on-year and contributing 0.33% of total Net Sales.
   Veterinary Pharmaceuticals Division recorded Net Sales of IDR 24.72 billion, a decrease of 11.15% from IDR
    27.83 billion in the same period of 2025. The division contributed 0.14% of the Company's total Net Sales.

About Enseval
PT Enseval Putera Megatrading Tbk ("Enseval") is one of Indonesia's largest distribution and logistics companies,
having commenced its business operations in 1973. The Company was listed on the Indonesia Stock Exchange
on August 1, 1994, under the ticker symbol EPMT.

In addition to distributing products from the Kalbe Group, Enseval is also entrusted by numerous domestic and
international principals. The Company is supported by an extensive distribution network consisting of three
Distribution Centers located in Jakarta, Cikarang, and Surabaya, 48 branches across Indonesia, and an
additional 24 branches operated through its subsidiary, PT Tri Sapta Jaya.

To date, the Company has eight subsidiaries engaged in distribution and logistics, raw materials, medical
devices, healthcare services, and transportation services.



Jakarta, July 31, 2026

For further information, please contact:
Corporate Secretary
PT Enseval Putera Megatrading Tbk
Enseval Building
Jalan Pulo Lentut No. 10
Pulo Gadung Industrial Estate, Jakarta 13920
Tel: (021) 4682-2422 Fax: (021) 460-9039
Email: investor.relations@enseval.com